Ivan Tornos - 19 Feb 2026 Form 4 Insider Report for ZIMMER BIOMET HOLDINGS, INC. (ZBH)

Reporting relationship: Chairman, President and CEO, Director
Issuer ticker: ZBH
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2026, 17:31:39 UTC
Prior SEC filing: 07 Mar 2025
Next SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew R. St. Louis, Attorney-in-Fact for Ivan Tornos (power of attorney previously filed)

Key filing fact

Ivan Tornos filed Form 4 for ZIMMER BIOMET HOLDINGS, INC. (ZBH) on 23 Feb 2026.

Key facts

This page summarizes Ivan Tornos's Form 4 filing for ZIMMER BIOMET HOLDINGS, INC. (ZBH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2026, 17:31.

Change

Previous filing in this sequence was filed on 07 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001757216 Primary reporting owner

Tornos Ivan

Relationship: Chairman, President and CEO, Director
Address: 345 E. MAIN STREET, WARSAW
Signature: /s/ Matthew R. St. Louis, Attorney-in-Fact for Ivan Tornos (power of attorney previously filed)
Signature date: 23 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZBH transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +24,436
Change %
Price: $0.000000
Shares after: 24,436
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,436
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each RSU represents a contingent right to receive one share of Company common stock.

Footnote F2

On March 6, 2023, and on September 1, 2023, the reporting person was granted performance-based RSUs, with the number of RSUs earned for both such grants to be determined based on the extent to which certain performance conditions were met for a performance period of 2023 - 2025. As determined on February 19, 2026, based on actual performance, the reporting person earned 12,184 RSUs for March and 12,252 RSUs for September, totaling 24,436 RSUs, which will vest on March 6, 2026.